Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions.
paper
Cited
Public
- Authors
- Swistowski, Andrzej; Peng, Jun; Liu, Qiuyue; Mali, Prashant; Rao, Mahendra S; Cheng, Linzhao; Zeng, Xianmin
- Year
- 2010
- Journal
- Stem cells (Dayton, Ohio)
- PMID
- 20715183
- DOI
- 10.1002/stem.499
- PMCID
- PMC2996088
Human induced pluripotent stem cells (iPSCs) reprogrammed from somatic cells represent a promising unlimited cell source for generating patient-specific cells for biomedical research and personalized medicine. As a first step, critical to clinical applications, we attempted to develop defined culture conditions to expand and differentiate human iPSCs into functional progeny such as dopaminergic neurons for treating or modeling Parkinson's disease (PD). We used a completely defined (xeno-free) system that we previously developed for efficient generation of authentic dopaminergic neurons from human embryonic stem cells (hESCs), and applied it to iPSCs. First, we adapted two human iPSC lines derived from different somatic cell types for the defined expansion medium and showed that the iPSCs grew similarly as hESCs in the same medium regarding pluripotency and genomic stability. Second, by using these two independent adapted iPSC lines, we showed that the process of differentiation into committed neural stem cells (NSCs) and subsequently into dopaminergic neurons was also similar to hESCs. Importantly, iPSC-derived dopaminergic neurons were functional as they survived and improved behavioral deficits in 6-hydroxydopamine-leasioned rats after transplantation. In addition, iPSC-derived NSCs and neurons could be efficiently transduced by a baculoviral vector delivering episomal DNA for future gene function study and disease modeling using iPSCs. We also performed genome-wide microarray comparisons between iPSCs and hESCs, and we derived NSC and dopaminergic neurons. Our data revealed overall similarity and visible differences at a molecular level. Efficient generation of functional dopaminergic neurons under defined conditions will facilitate research and applications using PD patient-specific iPSCs.
Generation of neural stem cells (NSCs) from induced pluripotent stem cell (iPSC) lines adapted to defined medium. iPSC line MR31 at passage 15 was adapted to a chemically defined medium StemPro. (AβD): Morphology (A) and expression of the pluripotent markers Tra 1-60 (B), Oct4 (C), and SSEA4 (D) in iPSCs that were cultured in StemPro for 10 passages. (EβH): Generation of NSCs in defined conditions. Neural tube-like rosette structures (E) were formed in the center of the iPSC colonies after 12 days of differentiation. A monolayer of homogeneous NSCs (F) coexpressed Sox1 and nestin (G), and Musashi (H). (IβL): iPSC-deriver NSCs retained the capacity to differentiate into neurons (IβJ), astrocytes (K), and oligodendrocytes (L). Abbreviation: GFAP, Glial fibrillary acidic protein.
Efficient differentiation of induced pluripotent stem cell (iPSC)-derived NSCs into dopaminergic neurons. (AβD): iPSC-derived NSCs differentiated into midbrain dopaminergic neurons in defined media as seen by immunocytochemistry. The majority of the cells expressed Ξ²-III-tubulin and TH after 5 weeks of differentiation (AβC). Coexpression of A9 marker Girk2 in TH+ dopaminergic neurons (D). Differential expression of dopaminergic markers in dopaminergic neurons compared with NSCs by quantitative polymerase chain reaction (E). All the examined markers were upregulated in dopaminergic populations compared with NSCs. Abbreviations: AADC, Aromatic L-Amino Acid Decarboxylase; DAT, dopamine transporter; NSC, neural stem cell; TH, tyrosine hydroxylase.
Transplantation of induced pluripotent stem cell (iPSC)-derived cells into 6-hydroxydopamine (6-OHDA) Parkinson's disease (PD) rats. iPSC-derived dopaminergic neurons engrafted and ameliorated behavioral deficits in a PD model. (A): Amphetamine-induced rotations in 6-OHDA rats grafted with iPSC-derived neurons (20 days after the neural stem cell stage) showed significant rotational improvement 12 weeks after transplantation. (BβE): Histological analysis of a representative brain section showed that donor cells (human antigen-immunopositive cells) coexpressing TH survived in the graft sites 12 weeks post-transplantation. Abbreviation: TH, tyrosine hydroxylase.
Whole genomic analysis of iPSCs at different stages of dopaminergic differentiation by Illumina bead microarray. A total of nine samples (undifferentiated human embryonic stem cell [hESC] line H9, iPSC lines MR31 and MMW2, NSCs derived from H9, MR31, and MMW2, and dopaminergic neurons derived from H9, MR31, and MMW2) were analyzed by Illumina array and the results demonstrated similarities between hESC and iPSCs. (A): Dendrogram of unsupervised one-way hierarchical clustering analysis of global gene expression data in hESCs/iPSCs, NSCs, and dopaminergic neurons derived from hESCs/iPSCs. (B): Unsupervised two-way hierarchical cluster analysis of differentially expressed genes illustrated in a heat map. The samples include three groups, hESCs/iPSCs, NSCs, and dopaminergic neurons. Expression values are presented as the log2 signal value of the given gene. Abbreviations: DA, dopaminergic; iPSC, induced pluripotent stem cell; NSC, neural stem cell.
Efficient transduction of induced pluripotent stem cell (iPSC)-derived neural stem cells (NSCs) and neurons by baculoviral vector. iPSC-derived NSCs and neurons were transduced by a baculoviral vector carrying a GFP driven by the CMV promoter. (AβL): Fluorescence microscopy showed strong expression of GFP in iPSC-derived NSCs (87% of total cell were GFP+ by FACS) 24 hours post-transduction or day 36 neurons (90.3% of total cell were GFP+ by FACS) 2 days after transduction. Expression of GFP in human embryonic stem cell (hESC)-derived neurons was shown for comparison (E, F). Immunostaining of Ξ²-III tubulin confirmed that the majority of neurons coexpressed GFP in both iPSC-derived neurons (GβI) and hESC-derived neurons (JβL). Abbreviation: GFP, Green Fluorescent Protein; CMV, Cytomegalovirus; FACS, Fluorescence-Activated Cell Sorting.
1β20 of 44
Next β
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Differentiation of human iPSCs into dopaminergic neurons: comparative analysis of 2D and 3D protocols for disease modeling and pharmacology. | Marcotto GS et al. | β | 2026 | β |
| Investigating the efficacy, methods, and challenges of induced pluripotent stem cells (iPSC) therapy in Parkinson's disease. | Mustafa MA et al. | β | 2026 | β |
| Induced pluripotent stem cell-related approaches to generate dopaminergic neurons for Parkinson's disease. | Yi LX et al. | β | 2025 | β |
| Progression of differentiation of iPSCs into specific subtypes of neurons. | Wang J et al. | β | 2025 | β |
| Transcriptomic Analysis of CAD Cell Differentiation | Cevallos CA et al. | β | 2025 | β |
| Transcriptomic Analysis of CAD Cell Differentiation. | Cevallos CA et al. | β | 2025 | β |
| ApoE maintains neuronal integrity via microRNA and H3K27me3-mediated repression. | Tan J et al. | β | 2024 | β |
| Cell reprogramming therapy for Parkinson's disease. | Dong W et al. | β | 2024 | β |
| Drug Delivery Across the Blood-Brain Barrier: A New Strategy for the Treatment of Neurological Diseases. | Jiao Y et al. | β | 2024 | β |
| The Neuroanatomy of Induced Pluripotent Stem Cells: In Vitro Models of Subcortical Nuclei in Neurodegenerative Disorders. | Galgani A et al. | β | 2024 | β |
| Time-efficient strategies in human iPS cell-derived pancreatic progenitor differentiation and cryopreservation: advancing towards practical applications. | Genova E et al. | β | 2024 | β |
| Challenges in the clinical advancement of cell therapies for Parkinson's disease. | Skidmore S et al. | β | 2023 | β |
| Challenges involved in cell therapy for Parkinson's disease using human pluripotent stem cells. | Moon H et al. | β | 2023 | β |
| Development of brain organoid technology derived from iPSC for the neurodegenerative disease modelling: a glance through. | Jusop AS et al. | β | 2023 | β |
| Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke. | Nie L et al. | β | 2023 | β |
| Dopaminergic neurons derived from porcine induced pluripotent stem cell like cells function in the Lanyu pig model of Parkinson's disease. | Liao YJ et al. | β | 2023 | β |
| Electrochemical Detection of Dopamine Release from Living Neurons Using Graphene Oxide-Incorporated Polypyrrole/Gold Nanocluster Hybrid Nanopattern Arrays. | Cho YW et al. | β | 2023 | β |
| From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy. | Yeap YJ et al. | β | 2023 | β |
| Human-Derived Cortical Neurospheroids Coupled to Passive, High-Density and 3D MEAs: A Valid Platform for Functional Tests. | Muzzi L et al. | β | 2023 | β |
| Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease. | Zheng X et al. | β | 2023 | β |
| Microglia-secreted TNF-Ξ± affects differentiation efficiency and viability of pluripotent stem cell-derived human dopaminergic precursors. | Wenker SD et al. | β | 2023 | β |
| Opportunities and limitations for studying neuropsychiatric disorders using patient-derived induced pluripotent stem cells. | Hong Y et al. | β | 2023 | β |
| Therapeutic efficacy and promise of stem cell-derived extracellular vesicles in Alzheimer's disease and other aging-related disorders. | Rather HA et al. | β | 2023 | β |
| Using Human-Induced Pluripotent Stem Cell Derived Neurons on Microelectrode Arrays to Model Neurological Disease: A Review. | Lv S et al. | β | 2023 | β |
| Combination of stem cell therapy and acupuncture to treat ischemic stroke: a prospective review. | Jia H et al. | β | 2022 | β |
| Gradient biomimetic platforms for neurogenesis studies. | Havins L et al. | β | 2022 | β |
| Identification of DOT1L inhibitor in a screen for factors that promote dopaminergic neuron survival. | Cui J et al. | β | 2022 | β |
| Magnetic Nanobubble Mechanical Stress Induces the Piezo1-Ca<sup>2+</sup> -BMP2/Smad Pathway to Modulate Neural Stem Cell Fate and MRI/Ultrasound Dual Imaging Surveillance for Ischemic Stroke. | Li J et al. | β | 2022 | β |
| Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives. | Rahman MM et al. | β | 2022 | β |
| Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays? | Sala-Jarque J et al. | β | 2022 | β |
| Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. | Lucido MJ et al. | β | 2021 | β |
| Current State-of-the-Art and Unresolved Problems in Using Human Induced Pluripotent Stem Cell-Derived Dopamine Neurons for Parkinson's Disease Drug Development. | Antonov SA et al. | β | 2021 | β |
| Emerging Brain-Pathophysiology-Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip. | Bang S et al. | β | 2021 | β |
| Microglia-Secreted Factors Enhance Dopaminergic Differentiation of Tissue- and iPSC-Derived Human Neural Stem Cells. | Schmidt SI et al. | β | 2021 | β |
| Novel test strategies for in vitro seizure liability assessment. | Tukker AM et al. | β | 2021 | β |
| Systematic evaluation of multiple qPCR platforms, NanoString and miRNA-Seq for microRNA biomarker discovery in human biofluids. | Hong LZ et al. | β | 2021 | β |
| The Evolving Role of Induced Pluripotent Stem Cells and Cerebral Organoids in Treating and Modeling Neurosurgical Diseases. | Jovanovich N et al. | β | 2021 | β |
| Advancement in the modelling and therapeutics of Parkinson's disease. | Rai SN et al. | β | 2020 | β |
| Current state of stem cell-based therapies: an overview. | Aly RM | β | 2020 | β |
| Differentiation and characterization of neurons derived from rat iPSCs. | Setien MB et al. | β | 2020 | β |
| Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease. | Harris JP et al. | β | 2020 | β |
| Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells. | Tran J et al. | β | 2020 | β |
| HSPGs glypican-1 and glypican-4 are human neuronal proteins characteristic of different neural phenotypes. | Oikari LE et al. | β | 2020 | β |
| Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. | Song B et al. | β | 2020 | β |
| Microglia Play an Essential Role in Synapse Development and Neuron Maturation in Tissue-Engineered Neural Tissues. | Zhu H et al. | β | 2020 | β |
| Modeling genetic epilepsies in a dish. | Niu W et al. | β | 2020 | β |
| Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons. | Schwartzentruber A et al. | β | 2020 | β |
| Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? | Gundersen V | β | 2020 | β |
| The <i>PARK10</i> gene <i>USP24</i> is a negative regulator of autophagy and ULK1 protein stability. | Thayer JA et al. | β | 2020 | β |
| The use of bioactive matrices in regenerative therapies for traumatic brain injury. | Tan HX et al. | β | 2020 | β |
| Adult Stem Cells and Induced Pluripotent Stem Cells for Stroke Treatment. | FernΓ‘ndez-Susavila H et al. | β | 2019 | β |
| An industry perspective: A streamlined screening strategy using alternative models for chemical assessment of developmental neurotoxicity. | Li J et al. | β | 2019 | β |
| Innovative models for <i>in vitro</i> detection of seizure. | Rockley KL et al. | β | 2019 | β |
| Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases. | Kumar S et al. | β | 2019 | β |
| Pluripotent stem cell-derived organogenesis in the rat model system. | Hirabayashi M et al. | β | 2019 | β |
| Recent progress in induced pluripotent stem cell-derived cardiac cell sheets for tissue engineering. | Gao B et al. | β | 2019 | β |
| Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. | Xue Y et al. | β | 2019 | β |
| Three-Dimensional Graphene Enhances Neural Stem Cell Proliferation Through Metabolic Regulation. | Fang Q et al. | β | 2019 | β |
| Typical halogenated flame retardants affect human neural stem cell gene expression during proliferation and differentiation via glycogen synthase kinase 3 beta and T3 signaling. | Liang S et al. | β | 2019 | β |
| Using induced pluripotent stem cells for modeling Parkinson's disease. | Ke M et al. | β | 2019 | β |
| Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting. | Fabre KM et al. | β | 2019 | β |
| Age-Related Epigenetic Derangement upon Reprogramming and Differentiation of Cells from the Elderly. | Ravaioli F et al. | β | 2018 | β |
| Calcium, Sodium, and Transient Receptor Potential Channel Expression in Human Fetal Midbrain-Derived Neural Progenitor Cells. | Stanslowsky N et al. | β | 2018 | β |
| Clinical Applications of Induced Pluripotent Stem Cells - Stato Attuale. | Kavyasudha C et al. | β | 2018 | β |
| Directing neuronal cell fate in vitro: Achievements and challenges. | Riemens RJM et al. | β | 2018 | β |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | β | 2018 | β |
| Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers. | Shafa M et al. | β | 2018 | β |
| Illustrating the potency of current Good Manufacturing Practice-compliant induced pluripotent stem cell lines as a source of multiple cell lineages using standardized protocols. | Rao MS et al. | β | 2018 | β |
| Induced pluripotent stem cells in rat models of Parkinson's disease: A systematic review and meta-analysis. | Zhang Y et al. | β | 2018 | β |
| Looking into the Future: Toward Advanced 3D Biomaterials for Stem-Cell-Based Regenerative Medicine. | Liu Z et al. | β | 2018 | β |
| Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. | Sonntag KC et al. | β | 2018 | β |
| Selective vulnerability in neurodegenerative diseases. | Fu H et al. | β | 2018 | β |
| Sequential Application of Discrete Topographical Patterns Enhances Derivation of Functional Mesencephalic Dopaminergic Neurons from Human Induced Pluripotent Stem Cells. | Tan KKB et al. | β | 2018 | β |
| SLC6 Transporter Folding Diseases and Pharmacochaperoning. | Freissmuth M et al. | β | 2018 | β |
| The Efficacy of Graphene Foams for Culturing Mesenchymal Stem Cells and Their Differentiation into Dopaminergic Neurons. | Tasnim N et al. | β | 2018 | β |
| Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease. | Struzyna LA et al. | β | 2018 | β |
| Brain imaging genetics in ADHD and beyond - Mapping pathways from gene to disorder at different levels of complexity. | Klein M et al. | β | 2017 | β |
| Early onset of inflammation during ontogeny of bipolar disorder: the NLRP2 inflammasome gene distinctly differentiates between patients and healthy controls in the transition between iPS cell and neural stem cell stages. | Vizlin-Hodzic D et al. | β | 2017 | β |
| Effects of Noggin-Transfected Neural Stem Cells on Neural Functional Recovery and Underlying Mechanism in Rats with Cerebral Ischemia Reperfusion Injury. | Zhu JD et al. | β | 2017 | β |
| Efficient generation of hPSC-derived midbrain dopaminergic neurons in a fully defined, scalable, 3D biomaterial platform. | Adil MM et al. | β | 2017 | β |
| Emerging Biofabrication Strategies for Engineering Complex Tissue Constructs. | Pedde RD et al. | β | 2017 | β |
| Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology. | Rawat N et al. | β | 2017 | β |
| In vitro differentiation of neural stem cells derived from human olfactory bulb into dopaminergic-like neurons. | Alizadeh R et al. | β | 2017 | β |
| Live Imaging Mitochondrial Transport in Neurons. | Course MM et al. | β | 2017 | β |
| Modeling neurodevelopmental and psychiatric diseases with human iPSCs. | Wen Z | β | 2017 | β |
| Old and new challenges in Parkinson's disease therapeutics. | Pires AO et al. | β | 2017 | β |
| Scaffolds for 3D in vitro culture of neural lineage cells. | Murphy AR et al. | β | 2017 | β |
| Understanding Parkinson's Disease through the Use of Cell Reprogramming. | Playne R et al. | β | 2017 | β |
| Use of Human Neurons Derived via Cellular Reprogramming Methods to Study Host-Parasite Interactions of Toxoplasma gondii in Neurons. | Halonen SK | β | 2017 | β |
| Beneath the sword of Damocles: regenerative medicine and the shadow of immunogenicity. | Fairchild PJ et al. | β | 2016 | β |
| Cell therapy for Parkinson's disease: Functional role of the host immune response on survival and differentiation of dopaminergic neuroblasts. | Wenker SD et al. | β | 2016 | β |
| Clinical translation of stem cell transplantation in Parkinson's disease. | Lindvall O | β | 2016 | β |
| Comparative neurotoxicity screening in human iPSC-derived neural stem cells, neurons and astrocytes. | Pei Y et al. | β | 2016 | β |
| Effects and mechanisms of melatonin on neural differentiation of induced pluripotent stem cells. | Shu T et al. | β | 2016 | β |
| Efficient derivation of dopaminergic neurons from SOX1β» floor plate cells under defined culture conditions. | Li M et al. | β | 2016 | β |
| Efficient generation of dopaminergic-like neurons by overexpression of Nurr1 and Pitx3 in mouse induced Pluripotent Stem Cells. | Salemi S et al. | β | 2016 | β |
| Glial progenitor cell-based treatment of the childhood leukodystrophies. | Osorio MJ et al. | β | 2016 | β |
| High-throughput compound evaluation on 3D networks of neurons and glia in a microfluidic platform. | Wevers NR et al. | β | 2016 | β |
| Induced Pluripotent Stem Cells as a Novel Tool in Psychiatric Research. | Kim S et al. | β | 2016 | β |
| Induced Pluripotent Stem Cell Therapies for Cervical Spinal Cord Injury. | Doulames VM et al. | β | 2016 | β |
| Influence of 6-Hydroxydopamine Toxicity on Ξ±-Synuclein Phosphorylation, Resting Vesicle Expression, and Vesicular Dopamine Release. | Ganapathy K et al. | β | 2016 | β |
| Influence of surface roughness on neural differentiation of human induced pluripotent stem cells. | Li Z et al. | β | 2016 | β |
| Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells. | Mungenast AE et al. | β | 2016 | β |
| Modeling psychiatric disorders with patient-derived iPSCs. | Wen Z et al. | β | 2016 | β |
| Reverse engineering liver buds through self-driven condensation and organization towards medical application. | Shinozawa T et al. | β | 2016 | β |
| The effect of magnetic nanoparticles on neuronal differentiation of induced pluripotent stem cell-derived neural precursors. | JirΓ‘kovΓ‘ K et al. | β | 2016 | β |
| A constraint-based modelling approach to metabolic dysfunction in Parkinson's disease. | Mao L et al. | β | 2015 | β |
| Cell reprogramming and neuronal differentiation applied to neurodegenerative diseases: Focus on Parkinson's disease. | Wenker SD et al. | β | 2015 | β |
| cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications. | Baghbaderani BA et al. | β | 2015 | β |
| Characterization of human neural differentiation from pluripotent stem cells using proteomics/PTMomics--current state-of-the-art and challenges. | Melo-Braga MN et al. | β | 2015 | β |
| Differentiation of neuroepithelial stem cells into functional dopaminergic neurons in 3D microfluidic cell culture. | Moreno EL et al. | β | 2015 | β |
| Elevated Ξ±-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells. | Oliveira LM et al. | β | 2015 | β |
| Human oligodendrocytes in remyelination research. | Czepiel M et al. | β | 2015 | β |
| Isolation of Human Neural Stem Cells from the Amniotic Fluid with Diagnosed Neural Tube Defects. | Chang YJ et al. | β | 2015 | β |
| Optimizing Differentiation Protocols for Producing Dopaminergic Neurons from Human Induced Pluripotent Stem Cells for Tissue Engineering Applications: Supplementary Issue: Stem Cell Biology. | Robinson M et al. | β | 2015 | β |
| Striatal Transplantation of Human Dopaminergic Neurons Differentiated From Induced Pluripotent Stem Cells Derived From Umbilical Cord Blood Using Lentiviral Reprogramming. | Effenberg A et al. | β | 2015 | β |
| The State of Play with iPSCs and Spinal Cord Injury Models. | Hodgetts SI et al. | β | 2015 | β |
| Treatment of Parkinson's disease using cell transplantation. | Lindvall O | β | 2015 | β |
| Using Patient-Derived Induced Pluripotent Stem Cells to Model and Treat Epilepsies. | Du X et al. | β | 2015 | β |
| Adipocytes derived from PA6 cells reliably promote the differentiation of dopaminergic neurons from human embryonic stem cells. | Guloglu MO et al. | β | 2014 | β |
| Adult subventricular zone neural stem cells as a potential source of dopaminergic replacement neurons. | Cave JW et al. | β | 2014 | β |
| Comparison and optimization of hiPSC forebrain cortical differentiation protocols. | Muratore CR et al. | β | 2014 | β |
| Comprehensive quantitative comparison of the membrane proteome, phosphoproteome, and sialiome of human embryonic and neural stem cells. | Melo-Braga MN et al. | β | 2014 | β |
| Concise review: drug discovery in the age of the induced pluripotent stem cell. | Ko HC et al. | β | 2014 | β |
| Detailed analysis of the genetic and epigenetic signatures of iPSC-derived mesodiencephalic dopaminergic neurons. | Roessler R et al. | β | 2014 | β |
| Direct lineage reprogramming of mouse fibroblasts to functional midbrain dopaminergic neuronal progenitors. | Kim HS et al. | β | 2014 | β |
| Functional differentiation of midbrain neurons from human cord blood-derived induced pluripotent stem cells. | Stanslowsky N et al. | β | 2014 | β |
| Functional screening assays with neurons generated from pluripotent stem cell-derived neural stem cells. | Efthymiou A et al. | β | 2014 | β |
| Genome wide profiling of dopaminergic neurons derived from human embryonic and induced pluripotent stem cells. | MomΔiloviΔ O et al. | β | 2014 | β |
| HIV/AIDS: modified stem cells in the spotlight. | Armijo E et al. | β | 2014 | β |
| Induced pluripotent stem cell potential in medicine, specifically focused on reproductive medicine. | Botman O et al. | β | 2014 | β |
| Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics? | de LΓ‘zaro I et al. | β | 2014 | β |
| Perspectives and future directions of human pluripotent stem cell-based therapies: lessons from Geron's clinical trial for spinal cord injury. | Lukovic D et al. | β | 2014 | β |
| Primary cilia in stem cells and neural progenitors are regulated by neutral sphingomyelinase 2 and ceramide. | He Q et al. | β | 2014 | β |
| Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neurons. | Sagal J et al. | β | 2014 | β |
| Stem cells and the treatment of Parkinson's disease. | Ali F et al. | β | 2014 | β |
| Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells. | Srikanth P et al. | β | 2014 | β |
| Survival and engraftment of dopaminergic neurons manufactured by a Good Manufacturing Practice-compatible process. | Peng J et al. | β | 2014 | β |
| The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies. | Scheiner ZS et al. | β | 2014 | β |
| The potential of alternate sources of cells for neural grafting in Parkinson's and Huntington's disease. | Drouin-Ouellet J | β | 2014 | β |
| Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? | Buttery PC et al. | β | 2014 | β |
| Adult bone marrow neural crest stem cells and mesenchymal stem cells are not able to replace lost neurons in acute MPTP-lesioned mice. | Neirinckx V et al. | β | 2013 | β |
| Directed neuronal differentiation of mouse embryonic and induced pluripotent stem cells and their gene expression profiles. | Chen X et al. | β | 2013 | β |
| Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? | Kansara S et al. | β | 2013 | β |
| ECM-dependent HIF induction directs trophoblast stem cell fate via LIMK1-mediated cytoskeletal rearrangement. | Choi HJ et al. | β | 2013 | β |
| Efficient generation of astrocytes from human pluripotent stem cells in defined conditions. | Shaltouki A et al. | β | 2013 | β |
| Engineering stem cells for future medicine. | Ricotti L et al. | β | 2013 | β |
| Genome editing of human pluripotent stem cells to generate human cellular disease models. | Musunuru K | β | 2013 | β |
| Highly efficient differentiation of neural precursors from human embryonic stem cells and benefits of transplantation after ischemic stroke in mice. | Drury-Stewart D et al. | β | 2013 | β |
| Hypoxia promotes dopaminergic differentiation of mesenchymal stem cells and shows benefits for transplantation in a rat model of Parkinson's disease. | Wang Y et al. | β | 2013 | β |
| Induced pluripotency for translational research. | Wu M et al. | β | 2013 | β |
| Induced pluripotent stem cells and their potential for basic and clinical sciences. | Ye L et al. | β | 2013 | β |
| Inhibitory effects of neural stem cells derived from human embryonic stem cells on differentiation and function of monocyte-derived dendritic cells. | Shahbazi M et al. | β | 2013 | β |
| Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease. | Skibinski G et al. | β | 2013 | β |
| Neural progenitors derived from human induced pluripotent stem cells survive and differentiate upon transplantation into a rat model of amyotrophic lateral sclerosis. | Popescu IR et al. | β | 2013 | β |
| Neural regeneration. | Steward MM et al. | β | 2013 | β |
| New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism. | Teo AK et al. | β | 2013 | β |
| Optimizing dopaminergic differentiation of pluripotent stem cells for the manufacture of dopaminergic neurons for transplantation. | Liu Q et al. | β | 2013 | β |
| Patient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate models. | Qiu Z et al. | β | 2013 | β |
| Pluripotent stem cells for Parkinson's disease: progress and challenges. | Zeng X et al. | β | 2013 | β |
| Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases. | Gao A et al. | β | 2013 | β |
| Repair of the CNS using endogenous and transplanted neural stem cells. | Trueman RC et al. | β | 2013 | β |
| Standardized generation and differentiation of neural precursor cells from human pluripotent stem cells. | Kozhich OA et al. | β | 2013 | β |
| Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury. | Kramer AS et al. | β | 2013 | β |
| Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. | Peng J et al. | β | 2013 | β |
| Veterinary applications of induced pluripotent stem cells: regenerative medicine and models for disease? | Cebrian-Serrano A et al. | β | 2013 | β |
| Will brain cells derived from induced pluripotent stem cells or directly converted from somatic cells (iNs) be useful for schizophrenia research? | Filippich C et al. | β | 2013 | β |
| Adult bone marrow: which stem cells for cellular therapy protocols in neurodegenerative disorders? | Wislet-Gendebien S et al. | β | 2012 | β |
| Calcium signaling in pluripotent stem cells. | ApΓ‘ti Γ et al. | β | 2012 | β |
| Cellular reprogramming: a new approach to modelling Parkinson's disease. | Hartfield EM et al. | β | 2012 | β |
| Clinical application of stem cell therapy in Parkinson's disease. | Politis M et al. | β | 2012 | β |
| Comparison of neural differentiation potential of human pluripotent stem cell lines using a quantitative neural differentiation protocol. | Yin D et al. | β | 2012 | β |
| Concise review: Human cell engineering: cellular reprogramming and genome editing. | Mali P et al. | β | 2012 | β |
| Converted neural cells: induced to a cure? | Zhang W et al. | β | 2012 | β |
| Dopaminergic differentiation using pluripotent stem cells. | MomΔiloviΔ O et al. | β | 2012 | β |
| Dopaminergic neuronal conversion from adult rat skeletal muscle-derived stem cells in vitro. | Yang J et al. | β | 2012 | β |
| From skin biopsy to neurons through a pluripotent intermediate under Good Manufacturing Practice protocols. | Karumbayaram S et al. | β | 2012 | β |
| Generation and applications of human pluripotent stem cells induced into neural lineages and neural tissues. | Martinez Y et al. | β | 2012 | β |
| Generation of Reactive Oxygen Species (ROS) and Pro-Inflammatory Signaling in Human Brain Cells in Primary Culture. | Lukiw WJ et al. | β | 2012 | β |
| Human induced pluripotent stem cells--from mechanisms to clinical applications. | Drews K et al. | β | 2012 | β |
| Human neural crest stem cells derived from human ESCs and induced pluripotent stem cells: induction, maintenance, and differentiation into functional schwann cells. | Liu Q et al. | β | 2012 | β |
| Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening. | Song M et al. | β | 2012 | β |
| Induced pluripotent stem cells: progress and future perspectives in the stem cell world. | Rezanejad H et al. | β | 2012 | β |
| Induced pluripotent stem cells: the new patient? | Bellin M et al. | β | 2012 | β |
| In vivo tumorigenesis was observed after injection of in vitro expanded neural crest stem cells isolated from adult bone marrow. | Wislet-Gendebien S et al. | β | 2012 | β |
| iPSC-derived fibroblasts demonstrate augmented production and assembly of extracellular matrix proteins. | Shamis Y et al. | β | 2012 | β |
| Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. | De Feo D et al. | β | 2012 | β |
| New lessons learned from disease modeling with induced pluripotent stem cells. | Onder TT et al. | β | 2012 | β |
| Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything? | Drouin-Ouellet J et al. | β | 2012 | β |
| Progress on stem cell research towards the treatment of Parkinson's disease. | Gibson SA et al. | β | 2012 | β |
| Reprogramming cellular identity for regenerative medicine. | Cherry AB et al. | β | 2012 | β |
| Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. | Mak SK et al. | β | 2012 | β |
| Standardization of pluripotent stem cell cultures for toxicity testing. | Pistollato F et al. | β | 2012 | β |
| Stem cells as in vitro model of Parkinson's disease. | MartΓnez-Morales PL et al. | β | 2012 | β |
| The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk. | Kumar KK et al. | β | 2012 | β |
| The potential of iPS cells in synucleinopathy research. | Linta L et al. | β | 2012 | β |
| A reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells. | Birket MJ et al. | β | 2011 | β |
| Cell-based therapies for Parkinson's disease. | Dyson SC et al. | β | 2011 | β |
| Cell therapeutics in Parkinson's disease. | Lindvall O et al. | β | 2011 | β |
| Cell therapy for multiple sclerosis. | Ben-Hur T | β | 2011 | β |
| Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. | Pedrosa E et al. | β | 2011 | β |
| Drug discovery in Parkinson's disease-Update and developments in the use of cellular models. | Skibinski G et al. | β | 2011 | β |
| Gene expression profiling of embryonic human neural stem cells and dopaminergic neurons from adult human substantia nigra. | Marei HE et al. | β | 2011 | β |
| Harnessing the potential of induced pluripotent stem cells for regenerative medicine. | Wu SM et al. | β | 2011 | β |
| Induced pluripotent stem cells and neurodegenerative diseases. | Chen C et al. | β | 2011 | β |
| Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. | Pessach IM et al. | β | 2011 | β |
| Induced pluripotent stem cells for modelling human diseases. | Unternaehrer JJ et al. | β | 2011 | β |
| Induced pluripotent stem cells in the study of neurological diseases. | Saporta MA et al. | β | 2011 | β |
| Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. | Grskovic M et al. | β | 2011 | β |
| Inducing iPSCs to escape the dish. | Barrilleaux B et al. | β | 2011 | β |
| Intracerebral transplantation for neurological disorders. Lessons from developmental, experimental, and clinical studies. | Benchoua A et al. | β | 2011 | β |
| In vitro optimization of retinoic acid-induced neuritogenesis and TH endogenous expression in human SH-SY5Y neuroblastoma cells by the antioxidant Trolox. | da Frota Junior ML et al. | β | 2011 | β |
| Patient-specific pluripotent stem cells in neurological diseases. | Durnaoglu S et al. | β | 2011 | β |
| Pituitary stem cell update and potential implications for treating hypopituitarism. | Castinetti F et al. | β | 2011 | β |
| Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. | Rhee YH et al. | β | 2011 | β |
| RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. | Lin M et al. | β | 2011 | β |
| Specification of neuronal and glial subtypes from human pluripotent stem cells. | Liu H et al. | β | 2011 | β |
| Steady advance of stem cell therapies: report from the 2011 World Stem Cell Summit, Pasadena, California, October 3-5. | Swan M | β | 2011 | β |
| The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. | Peng J et al. | β | 2011 | β |